Biobanking Market Report Scope & Overview
The Biobanking Market size was valued at USD 76.68 billion in 2023, and is expected to reach USD 151.11 billion by 2031 and grow at a CAGR of 8.85% over the forecast period 2024-2031.
The Biobanks are essentially large-scale storage facilities for human biological samples like blood, tissues, and cells. They act as vital resources for medical research. This field has seen significant advancements, with the incorporation of advanced technologies, data analysis tools, and automation. This transformation has led to the rise of "virtual biobanks," which offer a whole new level of market potential.
Get more information on Biobanking Market - Request Sample Report
Some biobanks specialize in specific diseases like cancer, while others collect samples from a wider population for general research. Tissue banks and blood banks are also variations within the biobanking landscape. Several factors are driving the biobanking market forward. There's a continuous rise in investments for developing new drugs. Researchers rely heavily on bio banked samples to test and refine these medications. The unfortunate reality of an increasing prevalence of diseases like cancer, respiratory illnesses, and Alzheimer disease necessitates the use of biobanks for in-depth research to combat them.
MARKET DYNAMICS:
KEY DRIVERS:
Growing Recognition and Investments Fueling the Rise of Biobanks
The Biobanks are receiving the support from governments, research institutions, and funding bodies around the world. Thus, more cash being poured into biobank improvement. A prime illustration is the Biorepository and Precision Medicine Initiative Cohort Program in the US. Financed by the National Institutes of Health, it aims to collect the biological samples from the tremendous number of an individuals to make a national research treasure trove. The Europe is on board with the Biobanking and Biomolecular Resources Research Infrastructure, a continent-wide effort to build a robust infrastructure for biobanking and biomolecular resources.
RESTRAINTS:
High Cost of Automation May Hinder Biobanking Market Growth Despite Efficiency Benefits
The biobanking might face a problem due to the high cost of this equipment. Advanced systems for handling samples can significantly improve efficiency and quality in biobanks. These tools are costly, especially for smaller institutions or those with limited budgets. The automated storage systems can range from tens to hundreds of thousands of dollars depending on their complexity.
OPPORTUNITIES:
Rising awareness of rare diseases opens doors for biobanks specializing in collecting samples from underrepresented populations.
Advancements in automation and data management improve biobank efficiency, attracting more research collaborations.
CHALLENGES:
Ensuring ethical and secure data collection and storage of sensitive samples is crucial.
Maintaining sample quality throughout storage and retrieval processes requires careful protocols.
IMPACT OF RUSSIA-UKRAINE WAR
The war in Russia-Ukraine is disrupting the supply chains for essential equipment and consumables used in biobanking are estimated to cause a 15-20% decrease in imports to affected regions. This can hinder the ability to establish or expand biobanking facilities, especially in war-torn areas like Ukraine. The war estimates a potential 20-30% drop in research personnel in Ukraine, stalling ongoing biobanking projects and hindering international collaborations that are crucial for scientific progress. It can divert funding away from scientific research towards war efforts. There is about 5-10% of decline in research funding allocated to biobanking initiatives in neighbouring countries due to redirected resources. These disruptions have caused in delaying the advancements in medical research that rely on bio-banked samples.
IMPACT OF ECONOMIC SLOWDOWN
An economic slowdown could disrupt the market's growth due to the limited government budgets, leading to less public funding for biobanking initiatives. Private companies, which heavily rely on biobanks for research, could limit their investments by an estimated 10-15% during a recession. This lower funding could slow down progress significantly. With the lower budget, people might prioritize essentials over enrolling in biobanking programs. This potential drop in participant enrolment could limit the number of samples collected, hindering research efforts that depend on them. Maintaining proper storage facilities, equipment, and trained staff can become more expensive during an economic downturn. Thus, biobanks might need to cut costs by 5-10%, potentially impacting their efficiency or the quality of services they offer.
KEY MARKET SEGMENTS:
By Product
Biobanking Equipment is the dominating sub-segment in the Biobanking by-product Market holding around 40-50% of the market share due to the ongoing establishment of new biobanks and the need for specialized equipment for processing, storing, and transporting biospecimens. This includes freezers, cryogenic storage systems, incubators, and monitoring systems, all crucial for maintaining sample integrity.
By Service
Biobanking & Repository
Lab processing
Qualification/ Validation
Cold Chain Logistics
Other Services
Biobanking & Repository Services is the dominating sub-segment in the Biobanking Market by service holding around 30-35% of the market share as it offers comprehensive solutions for managing biobanks. Services like sample collection, processing, storage, and retrieval are essential for biobanks to function efficiently.
By Biospecimen Type
Human Tissues
Human Organs
Stem Cells
Adult Stem Cells
Embryonic Stem Cells
IPS Cells
Other Stem Cells
Other Biospecimens
Human Tissues is the dominating sub-segment in the Biobanking Market by biospecimen type due to the abundance of tissues that can be banked for research purposes, the relative ease of obtaining them compared to organs, and advancements in tissue storage technologies.
By Biobanks Type
Physical/Real Biobanks
Tissue Biobanks
Population Based Biobanks
Genetic (DNA/RNA)
Disease Based Biobanks
Virtual Biobanks
Physical Biobanks is the dominating sub-segment in the Biobanking Market by biobank type holding around 25-30% of the market share These biobanks gather samples from patients with specific diseases, making them invaluable for targeted research. The rising prevalence of chronic diseases and the push towards personalized medicine fuel their dominance.
By Application
Therapeutics
Drug Discovery & Clinical Research
Clinical Diagnostics
Other Applications
Drug Discovery & Clinical Research is the dominating sub-segment in the Biobanking Market by application as biobanks are a critical resource for developing new drugs and testing their effectiveness. The growing pharmaceutical industry and focus on innovative therapies drive this segment's dominance.
By Ownership
University Owned
National/Regional Agencies Owned
Non-profit Organizations Owned
Private Organization Owned
National/Regional Agencies Owned Biobanks is the dominating sub-segment in the Biobanking Market by ownership holding around 20-25% of market share .These biobanks often benefit from government funding and resources, allowing them to build large-scale facilities and collect extensive biospecimen collections. This fosters collaboration and supports research initiatives with a broader impact.
By End-use
Pharmaceutical & Biotechnology Companies
CROs & CMOs
Academic & Research Institutes
Hospitals
Pharmaceutical & Biotechnology Companies is the dominating sub-segment in the Biobanking Market by end-use. These companies heavily rely on biobanks for drug discovery and development, making them the primary end-users. Their significant investments in R&D contribute to this segment's leadership.
REGIONAL ANALYSES
Europe is the dominating region in the biobanking market holding about 39% of market share. This dominance stems from a long history of established biobanks, strong public support for funding and infrastructure, and a thriving research environment with numerous pharmaceutical and life science institutions driving demand for samples.
North America is the second highest region in this market, fueled by its focus on advanced technologies in biobanking and the presence of major clinical trials conducted by pharmaceutical giants.
The Asia Pacific is the fastest growing region this market. It is driven by government initiatives promoting biobanking, rising economic strength enabling greater investment in research, and the vast and diverse population base offering valuable resources for studying diseases and developing personalized medicine approaches.
Need any customization research on Biobanking Market - Enquiry Now
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton and other key players.
In Feb. 2023: PHC North America introduces the PHCbi VIP ECO SMART ultra-low temperature freezer, boasting industry-leading energy efficiency for labs and research institutions.
In Sept. 2022: Cryoport and BioLife Plasma Services join forces. Cryoport will provide BioLife with temperature-controlled logistics and specialized services for their plasma collection and processing.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 3.3 Billion |
| Market Size by 2031 | US$ 7.7 Billion |
| C1AGR | CAGR of 11.2% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments |
• By Product (Biobanking Equipment (Temperature Control Systems, Freezers & Refrigerators, Cryogenic Storage Systems, Thawing Equipment, Incubators & Centrifuges, Alarms & Monitoring Systems, Accessories & Other Equipment), Biobanking Consumables, Laboratory Information Management Systems) • By Service (Biobanking & Repository, Lab processing, Qualification/ Validation, Cold Chain Logistics, Other Services) • By Biospecimen Type (Human Tissues, Human Organs, Stem Cells (Adult Stem Cells, Embryonic Stem Cells, IPS Cells, Other Stem Cells), Other Biospecimens) • By Biobanks Type (Physical/Real Biobanks (Tissue Biobanks, Population Based Biobanks, Genetic (DNA/RNA), Disease Based Biobanks),Virtual Biobanks) • By Application (Therapeutics, Drug Discovery & Clinical Research, Clinical Diagnostics, Other Applications) • By Ownership (University Owned, National/Regional Agencies Owned, Non-profit Organizations Owned, Private Organization Owned) • By End-use (Pharmaceutical & Biotechnology Companies, CROs & CMOs, Academic & Research Institutes, Hospitals) |
| Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America |
| Company Profiles | Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton. |
| DRIVERS | • Biobanking advancements and the rising prevalence of saving newborns' cord blood stem cells • The demand for low-cost drug discovery and development is growing. • Supporting Regenerative Medicine Research with Public and Private Funding |
| OPPORTUNITIES | • Problems in Obtaining Biospecimen Samples • Automation's High Costs |
The expected CAGR of the global Biobanking Market during the forecast period is 8.85%.
The Biobanking Market was valued at USD 76.68 in 2023.
Growing importance of biobanks in medical research, rising chronic diseases, and the push towards personalized medicine.
University-owned, national agencies, and pharmaceutical & biotechnology companies.
Europe is the leading region in the biobanking market.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Biobanking Market Segmentation, By Product
9.1 Introduction
9.2 Trend Analysis
9.3 Biobanking Equipment
9.3.1 Temperature Control Systems
9.3.1.1 Freezers & Refrigerators
9.3.1.2 Cryogenic Storage Systems
9.3.1.3 Thawing Equipment
9.3.2 Incubators & Centrifuges
9.3.3 Alarms & Monitoring Systems
9.3.4 Accessories & Other Equipment
9.4 Biobanking Consumables
9.5 Laboratory Information Management Systems
10. Biobanking Market Segmentation, By Service
10.1 Introduction
10.2 Trend Analysis
10.3 Biobanking & Repository
10.4 Lab processing
10.5 Qualification/ Validation
10.6 Cold Chain Logistics
10.7 Other Services
11. Biobanking Market Segmentation, By Biospecimen Type
11.1 Introduction
11.2 Trend Analysis
11.3 Human Tissues
11.4 Human Organs
11.5 Stem Cells
11.5.1 Adult Stem Cells
11.5.2 Embryonic Stem Cells
11.5.3 IPS Cells
11.5.4 Other Stem Cells
11.6 Other Biospecimens
12. Biobanking Market Segmentation, By Biobanks Type
12.1 Introduction
12.2 Trend Analysis
12.3 Physical/Real Biobanks
12.3.1 Tissue Biobanks
12.3.2 Population Based Biobanks
12.3.3 Genetic (DNA/RNA)
12.3.4 Disease Based Biobanks
12.4 Virtual Biobanks
13. Biobanking Market Segmentation, By Application
13.1 Introduction
13.2 Trend Analysis
13.3 Therapeutics
13.4 Drug Discovery & Clinical Research
13.5 Clinical Diagnostics
13.6 Other Applications
14. Biobanking Market Segmentation, By Ownership
14.1 Introduction
14.2 Trend Analysis
14.3 University Owned
14.4 National/Regional Agencies Owned
14.5 Non-profit Organizations Owned
14.6 Private Organization Owned
15. Biobanking Market Segmentation, By End-use
15.1 Introduction
15.2 Trend Analysis
15.3 Pharmaceutical & Biotechnology Companies
15.4 CROs & CMOs
15.5 Academic & Research Institutes
15.6 Hospitals
16. Regional Analysis
16.1 Introduction
16.2 North America
16.2.1 Trend Analysis
16.2.2 North America Biobanking Market, By Country
16.2.3 North America Biobanking Market Segmentation, By Product
16.2.4 North America Biobanking Market Segmentation, By Service
16.2.5 North America Biobanking Market Segmentation, By Biospecimen Type
16.2.6 North America Biobanking Market Segmentation, By Biobanks Type
16.2.7 North America Biobanking Market Segmentation, By Application
16.2.8 North America Biobanking Market Segmentation, By Ownership
16.2.9 North America Biobanking Market Segmentation, By End-use
16.2.10 USA
16.2.10.1 USA Biobanking Market Segmentation, By Product
16.2.10.2 USA Biobanking Market Segmentation, By Service
16.2.10.3 USA Biobanking Market Segmentation, By Biospecimen Type
16.2.10.4 USA Biobanking Market Segmentation, By Biobanks Type
16.2.10.5 USA Biobanking Market Segmentation, By Application
16.2.10.6 USA Biobanking Market Segmentation, By Ownership
16.2.10.7 USA Biobanking Market Segmentation, By End-use
16.2.11 Canada
16.2.11.1 Canada Biobanking Market Segmentation, By Product
16.2.11.2 Canada Biobanking Market Segmentation, By Service
16.2.11.3 Canada Biobanking Market Segmentation, By Biospecimen Type
16.2.11.4 Canada Biobanking Market Segmentation, By Biobanks Type
16.2.11.5 Canada Biobanking Market Segmentation, By Application
16.2.11.6 Canada Biobanking Market Segmentation, By Ownership
16.2.11.7 Canada Biobanking Market Segmentation, By End-use
16.2.12 Mexico
16.2.12.1 Mexico Biobanking Market Segmentation, By Product
16.2.12.2 Mexico Biobanking Market Segmentation, By Service
16.2.12.3 Mexico Biobanking Market Segmentation, By Biospecimen Type
16.2.12.4 Mexico Biobanking Market Segmentation, By Biobanks Type
16.2.12.5 Mexico Biobanking Market Segmentation, By Application
16.2.12.6 Mexico Biobanking Market Segmentation, By Ownership
16.2.12.7 Mexico Biobanking Market Segmentation, By End-use
16.3 Europe
16.3.1 Trend Analysis
16.3.2 Eastern Europe
16.3.2.1 Eastern Europe Biobanking Market, By Country
16.3.2.2 Eastern Europe Biobanking Market Segmentation, By Product
16.3.2.3 Eastern Europe Biobanking Market Segmentation, By Service
16.3.2.4 Eastern Europe Biobanking Market Segmentation, By Biospecimen Type
16.3.2.5 Eastern Europe Biobanking Market Segmentation, By Biobanks Type
16.3.2.6 Eastern Europe Biobanking Market Segmentation, By Application
16.3.2.7 Eastern Europe Biobanking Market Segmentation, By Ownership
16.3.2.8 Eastern Europe Biobanking Market Segmentation, By End-use
16.3.2.9 Poland
16.3.2.9.1 Poland Biobanking Market Segmentation, By Product
16.3.2.9.2 Poland Biobanking Market Segmentation, By Service
16.3.2.9.3 Poland Biobanking Market Segmentation, By Biospecimen Type
16.3.2.9.4 Poland Biobanking Market Segmentation, By Biobanks Type
16.3.2.9.5 Poland Biobanking Market Segmentation, By Application
16.3.2.9.6 Poland Biobanking Market Segmentation, By Ownership
16.3.2.9.7 Poland Biobanking Market Segmentation, By End-use
16.3.2.10 Romania
16.3.2.10.1 Romania Biobanking Market Segmentation, By Product
16.3.2.10.2 Romania Biobanking Market Segmentation, By Service
16.3.2.10.3 Romania Biobanking Market Segmentation, By Biospecimen Type
16.3.2.10.4 Romania Biobanking Market Segmentation, By Biobanks Type
16.3.2.10.5 Romania Biobanking Market Segmentation, By Application
16.3.2.10.6 Romania Biobanking Market Segmentation, By Ownership
16.3.2.10.7 Romania Biobanking Market Segmentation, By End-use
16.3.2.11 Hungary
16.3.2.11.1 Hungary Biobanking Market Segmentation, By Product
16.3.2.11.2 Hungary Biobanking Market Segmentation, By Service
16.3.2.11.3 Hungary Biobanking Market Segmentation, By Biospecimen Type
16.3.2.11.4 Hungary Biobanking Market Segmentation, By Biobanks Type
16.3.2.11.5 Hungary Biobanking Market Segmentation, By Application
16.3.2.11.6 Hungary Biobanking Market Segmentation, By Ownership
16.3.2.11.7 Hungary Biobanking Market Segmentation, By End-use
16.3.2.12 Turkey
16.3.2.12.1 Turkey Biobanking Market Segmentation, By Product
16.3.2.12.2 Turkey Biobanking Market Segmentation, By Service
16.3.2.12.3 Turkey Biobanking Market Segmentation, By Biospecimen Type
16.3.2.12.4 Turkey Biobanking Market Segmentation, By Biobanks Type
16.3.2.12.5 Turkey Biobanking Market Segmentation, By Application
16.3.2.12.6 Turkey Biobanking Market Segmentation, By Ownership
16.3.2.12.7 Turkey Biobanking Market Segmentation, By End-use
16.3.2.13 Rest of Eastern Europe
16.3.2.13.1 Rest of Eastern Europe Biobanking Market Segmentation, By Product
16.3.2.13.2 Rest of Eastern Europe Biobanking Market Segmentation, By Service
16.3.2.13.3 Rest of Eastern Europe Biobanking Market Segmentation, By Biospecimen Type
16.3.2.13.4 Rest of Eastern Europe Biobanking Market Segmentation, By Biobanks Type
16.3.2.13.5 Rest of Eastern Europe Biobanking Market Segmentation, By Application
16.3.2.13.6 Rest of Eastern Europe Biobanking Market Segmentation, By Ownership
16.3.2.13.7 Rest of Eastern Europe Biobanking Market Segmentation, By End-use
16.3.3 Western Europe
16.3.3.1 Western Europe Biobanking Market, By Country
16.3.3.2 Western Europe Biobanking Market Segmentation, By Product
16.3.3.3 Western Europe Biobanking Market Segmentation, By Service
16.3.3.4 Western Europe Biobanking Market Segmentation, By Biospecimen Type
16.3.3.5 Western Europe Biobanking Market Segmentation, By Biobanks Type
16.3.3.6 Western Europe Biobanking Market Segmentation, By Application
16.3.3.7 Western Europe Biobanking Market Segmentation, By Ownership
16.3.3.8 Western Europe Biobanking Market Segmentation, By End-use
16.3.3.9 Germany
16.3.3.9.1 Germany Biobanking Market Segmentation, By Product
16.3.3.9.2 Germany Biobanking Market Segmentation, By Service
16.3.3.9.3 Germany Biobanking Market Segmentation, By Biospecimen Type
16.3.3.9.4 Germany Biobanking Market Segmentation, By Biobanks Type
16.3.3.9.5 Germany Biobanking Market Segmentation, By Application
16.3.3.9.6 Germany Biobanking Market Segmentation, By Ownership
16.3.3.9.7 Germany Biobanking Market Segmentation, By End-use
16.3.3.10 France
16.3.3.10.1 France Biobanking Market Segmentation, By Product
16.3.3.10.2 France Biobanking Market Segmentation, By Service
16.3.3.10.3 France Biobanking Market Segmentation, By Biospecimen Type
16.3.3.10.4 France Biobanking Market Segmentation, By Biobanks Type
16.3.3.10.5 France Biobanking Market Segmentation, By Application
16.3.3.10.6 France Biobanking Market Segmentation, By Ownership
16.3.3.10.7 France Biobanking Market Segmentation, By End-use
16.3.3.11 UK
16.3.3.11.1 UK Biobanking Market Segmentation, By Product
16.3.3.11.2 UK Biobanking Market Segmentation, By Service
16.3.3.11.3 UK Biobanking Market Segmentation, By Biospecimen Type
16.3.3.11.4 UK Biobanking Market Segmentation, By Biobanks Type
16.3.3.11.5 UK Biobanking Market Segmentation, By Application
16.3.3.11.6 UK Biobanking Market Segmentation, By Ownership
16.3.3.11.7 UK Biobanking Market Segmentation, By End-use
16.3.3.12 Italy
16.3.3.12.1 Italy Biobanking Market Segmentation, By Product
16.3.3.12.2 Italy Biobanking Market Segmentation, By Service
16.3.3.12.3 Italy Biobanking Market Segmentation, By Biospecimen Type
16.3.3.12.4 Italy Biobanking Market Segmentation, By Biobanks Type
16.3.3.12.5 Italy Biobanking Market Segmentation, By Application
16.3.3.12.6 Italy Biobanking Market Segmentation, By Ownership
16.3.3.12.7 Italy Biobanking Market Segmentation, By End-use
16.3.3.13 Spain
16.3.3.13.1 Spain Biobanking Market Segmentation, By Product
16.3.3.13.2 Spain Biobanking Market Segmentation, By Service
16.3.3.13.3 Spain Biobanking Market Segmentation, By Biospecimen Type
16.3.3.13.3 Spain Biobanking Market Segmentation, By Biobanks Type
16.3.3.13.4 Spain Biobanking Market Segmentation, By Application
16.3.3.13.6 Spain Biobanking Market Segmentation, By Ownership
16.3.3.13.7 Spain Biobanking Market Segmentation, By End-use
16.3.3.14 Netherlands
16.3.3.14.1 Netherlands Biobanking Market Segmentation, By Product
16.3.3.14.2 Netherlands Biobanking Market Segmentation, By Service
16.3.3.14.3 Netherlands Biobanking Market Segmentation, By Biospecimen Type
16.3.3.14.3 Netherlands Biobanking Market Segmentation, By Biobanks Type
16.3.3.14.4 Netherlands Biobanking Market Segmentation, By Application
16.3.3.14.6 Netherlands Biobanking Market Segmentation, By Ownership
16.3.3.14.7 Netherlands Biobanking Market Segmentation, By End-use
16.3.3.15 Switzerland
16.3.3.15.1 Switzerland Biobanking Market Segmentation, By Product
16.3.3.15.2 Switzerland Biobanking Market Segmentation, By Service
16.3.3.15.3 Switzerland Biobanking Market Segmentation, By Biospecimen Type
16.3.3.15.4 Switzerland Biobanking Market Segmentation, By Biobanks Type
16.3.3.15.5 Switzerland Biobanking Market Segmentation, By Application
16.3.3.15.6 Switzerland Biobanking Market Segmentation, By Ownership
16.3.3.15.7 Switzerland Biobanking Market Segmentation, By End-use
16.3.3.16 Austria
16.3.3.16.1 Austria Biobanking Market Segmentation, By Product
16.3.3.16.2 Austria Biobanking Market Segmentation, By Service
16.3.3.16.3 Austria Biobanking Market Segmentation, By Biospecimen Type
16.3.3.16.4 Austria Biobanking Market Segmentation, By Biobanks Type
16.3.3.16.5 Austria Biobanking Market Segmentation, By Application
16.3.3.16.6 Austria Biobanking Market Segmentation, By Ownership
16.3.3.16.7 Austria Biobanking Market Segmentation, By End-use
16.3.3.17 Rest of Western Europe
16.3.3.17.1 Rest of Western Europe Biobanking Market Segmentation, By Product
16.3.3.17.2 Rest of Western Europe Biobanking Market Segmentation, By Service
16.3.3.17.3 Rest of Western Europe Biobanking Market Segmentation, By Biospecimen Type
16.3.3.17.4 Rest of Western Europe Biobanking Market Segmentation, By Biobanks Type
16.3.3.17.5 Rest of Western Europe Biobanking Market Segmentation, By Application
16.3.3.17.6 Rest of Western Europe Biobanking Market Segmentation, By Ownership
16.3.3.17.7 Rest of Western Europe Biobanking Market Segmentation, By End-use
16.4 Asia-Pacific
16.4.1 Trend Analysis
16.4.2 Asia-Pacific Biobanking Market, By country
16.4.3 Asia-Pacific Biobanking Market Segmentation, By Product
16.4.4 Asia-Pacific Biobanking Market Segmentation, By Service
16.4.5 Asia-Pacific Biobanking Market Segmentation, By Biospecimen Type
16.4.6 Asia-Pacific Biobanking Market Segmentation, By Biobanks Type
16.4.7 Asia-Pacific Biobanking Market Segmentation, By Application
16.3.8 Asia-Pacific Biobanking Market Segmentation, By Ownership
16.3.9 Asia-Pacific Biobanking Market Segmentation, By End-use
16.4.10 China
16.4.10.1 China Biobanking Market Segmentation, By Product
16.4.10.2 China Biobanking Market Segmentation, By Service
16.4.10.3 China Biobanking Market Segmentation, By Biospecimen Type
16.4.10.4 China Biobanking Market Segmentation, By Biobanks Type
16.4.10.5 China Biobanking Market Segmentation, By Application
16.4.10.6 China Biobanking Market Segmentation, By Ownership
16.4.10.7 China Biobanking Market Segmentation, By End-use
16.4.11 India
16.4.11.1 India Biobanking Market Segmentation, By Product
16.4.11.2 India Biobanking Market Segmentation, By Service
16.4.11.3 India Biobanking Market Segmentation, By Biospecimen Type
16.4.11.4 India Biobanking Market Segmentation, By Biobanks Type
16.4.11.5 India Biobanking Market Segmentation, By Application
16.4.11.6 India Biobanking Market Segmentation, By Ownership
16.4.11.7 India Biobanking Market Segmentation, By End-use
16.4.12 Japan
16.4.12.1 Japan Biobanking Market Segmentation, By Product
16.4.12.2 Japan Biobanking Market Segmentation, By Service
16.4.12.3 Japan Biobanking Market Segmentation, By Biospecimen Type
16.4.12.4 Japan Biobanking Market Segmentation, By Biobanks Type
16.4.12.5 Japan Biobanking Market Segmentation, By Application
16.4.12.6 Japan Biobanking Market Segmentation, By Ownership
16.4.12.7 Japan Biobanking Market Segmentation, By End-use
16.4.13 South Korea
16.4.13.1 South Korea Biobanking Market Segmentation, By Product
16.4.13.2 South Korea Biobanking Market Segmentation, By Service
16.4.13.3 South Korea Biobanking Market Segmentation, By Biospecimen Type
16.4.13.4 South Korea Biobanking Market Segmentation, By Biobanks Type
16.4.13.5 South Korea Biobanking Market Segmentation, By Application
16.4.13.6 South Korea Biobanking Market Segmentation, By Ownership
16.4.13.7 South Korea Biobanking Market Segmentation, By End-use
16.4.14 Vietnam
16.4.14.1 Vietnam Biobanking Market Segmentation, By Product
16.4.14.2 Vietnam Biobanking Market Segmentation, By Service
16.4.14.3 Vietnam Biobanking Market Segmentation, By Biospecimen Type
16.4.14.4 Vietnam Biobanking Market Segmentation, By Biobanks Type
16.4.14.5 Vietnam Biobanking Market Segmentation, By Application
16.4.14.6 Vietnam Biobanking Market Segmentation, By Ownership
16.4.14.7 Vietnam Biobanking Market Segmentation, By End-use
16.4.15 Singapore
16.4.15.1 Singapore Biobanking Market Segmentation, By Product
16.4.15.2 Singapore Biobanking Market Segmentation, By Service
16.4.15.3 Singapore Biobanking Market Segmentation, By Biospecimen Type
16.4.15.4 Singapore Biobanking Market Segmentation, By Biobanks Type
16.4.15.5 Singapore Biobanking Market Segmentation, By Application
16.4.15.6 Singapore Biobanking Market Segmentation, By Ownership
16.4.15.7 Singapore Biobanking Market Segmentation, By End-use
16.4.16 Australia
16.4.16.1 Australia Biobanking Market Segmentation, By Product
16.4.16.2 Australia Biobanking Market Segmentation, By Service
16.4.16.3 Australia Biobanking Market Segmentation, By Biospecimen Type
16.4.16.4 Australia Biobanking Market Segmentation, By Biobanks Type
16.4.16.5 Australia Biobanking Market Segmentation, By Application
16.4.16.6 Australia Biobanking Market Segmentation, By Ownership
16.4.16.7 Australia Biobanking Market Segmentation, By End-use
16.4.17 Rest of Asia-Pacific
16.4.17.1 Rest of Asia-Pacific Biobanking Market Segmentation, By Product
16.4.17.2 Rest of Asia-Pacific Biobanking Market Segmentation, By Service
16.4.17.3 Rest of Asia-Pacific Biobanking Market Segmentation, By Biospecimen Type
16.4.17.4 Rest of Asia-Pacific Biobanking Market Segmentation, By Biobanks Type
16.4.17.5 Rest of Asia-Pacific Biobanking Market Segmentation, By Application
16.4.17.6 Rest of Asia-Pacific Biobanking Market Segmentation, By Ownership
16.4.17.7 Rest of Asia-Pacific Biobanking Market Segmentation, By End-use
16.5 Middle East & Africa
16.5.1 Trend Analysis
16.5.2 Middle East
16.5.2.1 Middle East Biobanking Market, By Country
16.5.2.2 Middle East Biobanking Market Segmentation, By Product
16.5.2.3 Middle East Biobanking Market Segmentation, By Service
16.5.2.4 Middle East Biobanking Market Segmentation, By Biospecimen Type
16.5.2.5 Middle East Biobanking Market Segmentation, By Biobanks Type
16.5.2.6 Middle East Biobanking Market Segmentation, By Application
16.4.2.7 Middle East Biobanking Market Segmentation, By Ownership
16.4.2.8 S Middle East ales Intelligence Market Segmentation, By End-use
16.5.2.9 UAE
16.5.2.9.1 UAE Biobanking Market Segmentation, By Product
16.5.2.9.2 UAE Biobanking Market Segmentation, By Service
16.5.2.9.3 UAE Biobanking Market Segmentation, By Biospecimen Type
16.5.2.9.4 UAE Biobanking Market Segmentation, By Biobanks Type
16.5.2.9.5 UAE Biobanking Market Segmentation, By Application
16.4.2.9.6 UAE Biobanking Market Segmentation, By Ownership
16.4.2.9.7 UAE Biobanking Market Segmentation, By End-use
16.5.2.10 Egypt
16.5.2.10.1 Egypt Biobanking Market Segmentation, By Product
16.5.2.10.2 Egypt Biobanking Market Segmentation, By Service
16.5.2.10.3 Egypt Biobanking Market Segmentation, By Biospecimen Type
16.5.2.10.4 Egypt Biobanking Market Segmentation, By Biobank Type
16.5.2.10.5 Egypt Biobanking Market Segmentation, By Application
16.4.2.10.6 Egypt Biobanking Market Segmentation, By Ownership
16.4.2.10.7 Egypt Biobanking Market Segmentation, By End-use
16.5.2.11 Saudi Arabia
16.5.2.11.1 Saudi Arabia Biobanking Market Segmentation, By Product
16.5.2.11.2 Saudi Arabia Biobanking Market Segmentation, By Service
16.5.2.11.3 Saudi Arabia Biobanking Market Segmentation, By Biospecimen Type
16.5.2.11.4 Saudi Arabia Biobanking Market Segmentation, By Biobank Type
16.5.2.11.5 Saudi Arabia Biobanking Market Segmentation, By Application
16.4.2.11.6 Saudi Arabia Biobanking Market Segmentation, By Ownership
16.4.2.11.7 Saudi Arabia Biobanking Market Segmentation, By End-use
16.5.2.12 Qatar
16.5.2.12.1 Qatar Biobanking Market Segmentation, By Product
16.5.2.12.2 Qatar Biobanking Market Segmentation, By Service
16.5.2.12.3 Qatar Biobanking Market Segmentation, By Biospecimen Type
16.5.2.12.4 Qatar Biobanking Market Segmentation, By Biobank Type
16.5.2.12.5 Qatar Biobanking Market Segmentation, By Application
16.4.2.12.6 Qatar Biobanking Market Segmentation, By Ownership
16.4.2.12.7 Qatar Biobanking Market Segmentation, By End-use
16.5.2.13 Rest of Middle East
16.5.2.13.1 Rest of Middle East Biobanking Market Segmentation, By Product
16.5.2.13.2 Rest of Middle East Biobanking Market Segmentation, By Service
16.5.2.13.3 Rest of Middle East Biobanking Market Segmentation, By Biospecimen Type
16.5.2.13.4 Rest of Middle East Biobanking Market Segmentation, By Biobank Type
16.5.2.13.5 Rest of Middle East Biobanking Market Segmentation, By Application
16.4.2.13.6 Rest of Middle East Biobanking Market Segmentation, By Ownership
16.4.2.13.7 Rest of Middle East Biobanking Market Segmentation, By End-use
16.5.3 Africa
16.5.3.1 Africa Biobanking Market, By Country
16.5.3.2 Africa Biobanking Market Segmentation, By Product
16.5.3.3 Africa Biobanking Market Segmentation, By Service
16.5.3.4 Africa Biobanking Market Segmentation, By Biospecimen Type
16.5.3.5 Africa Biobanking Market Segmentation, By Biobank Type
16.5.3.6 Africa Biobanking Market Segmentation, By Application
16.5.3.7 Africa Biobanking Market Segmentation, By Ownership
16.5.3.8 Africa Biobanking Market Segmentation, By End-use
16.5.3.9 Nigeria
16.5.3.9.1 Nigeria Biobanking Market Segmentation, By Product
16.5.3.9.2 Nigeria Biobanking Market Segmentation, By Service
16.5.3.9.3 Nigeria Biobanking Market Segmentation, By Biospecimen Type
16.5.3.9.4 Nigeria Biobanking Market Segmentation, By Biobank Type
16.5.3.9.5 Nigeria Biobanking Market Segmentation, By Application
16.5.3.9.6 Nigeria Biobanking Market Segmentation, By Ownership
16.5.3.9.7 Nigeria Biobanking Market Segmentation, By End-use
16.5.3.10 South Africa
16.5.3.10.1 South Africa Biobanking Market Segmentation, By Product
16.5.3.10.2 South Africa Biobanking Market Segmentation, By Service
16.5.3.10.3 South Africa Biobanking Market Segmentation, By Biospecimen Type
16.5.3.10.4 South Africa Biobanking Market Segmentation, By Biobank Type
16.5.3.10.5 South Africa Biobanking Market Segmentation, By Application
16.5.3.10.6 South Africa Biobanking Market Segmentation, By Ownership
16.5.3.10.7 South Africa Biobanking Market Segmentation, By End-use
16.5.3.11 Rest of Africa
16.5.3.11.1 Rest of Africa Biobanking Market Segmentation, By Product
16.5.3.11.2 Rest of Africa Biobanking Market Segmentation, By Service
16.5.3.11.3 Rest of Africa Biobanking Market Segmentation, By Biospecimen Type
16.5.3.11.4 Rest of Africa Biobanking Market Segmentation, By Biobank Type
16.5.3.11.5 Rest of Africa Biobanking Market Segmentation, By Application
16.5.3.11.6 Rest of Africa Biobanking Market Segmentation, By Ownership
16.5.3.11.7 Rest of Africa Biobanking Market Segmentation, By End-use
16.6 Latin America
16.6.1 Trend Analysis
16.6.2 Latin America Biobanking Market, By Country
16.6.3 Latin America Biobanking Market Segmentation, By Product
16.6.4 Latin America Biobanking Market Segmentation, By Service
16.6.5 Latin America Biobanking Market Segmentation, By Biospecimen Type
16.6.6 Latin America Biobanking Market Segmentation, By Biobank Type
16.6.7 Latin America Biobanking Market Segmentation, By Application
16.6.8 Latin America Biobanking Market Segmentation, By Ownership
16.6.9 Latin America Biobanking Market Segmentation, By End-use
16.6.10 Brazil
16.6.10.1 Brazil Biobanking Market Segmentation, By Product
16.6.10.2 Brazil Biobanking Market Segmentation, By Service
16.6.10.3 Brazil Biobanking Market Segmentation, By Biospecimen Type
16.6.10.4 Brazil Biobanking Market Segmentation, By Biobank Type
16.6.10.5 Brazil Biobanking Market Segmentation, By Application
16.6.10.6 Brazil Biobanking Market Segmentation, By Ownership
16.6.10.7 Brazil Biobanking Market Segmentation, By End-use
16.6.11 Argentina
16.6.11.1 Argentina Biobanking Market Segmentation, By Product
16.6.11.2 Argentina Biobanking Market Segmentation, By Service
16.6.11.3 Argentina Biobanking Market Segmentation, By Biospecimen Type
16.6.11.3 Argentina Biobanking Market Segmentation, By Biobank Type
16.6.11.4 Argentina Biobanking Market Segmentation, By Application
16.6.11.6 Argentina Biobanking Market Segmentation, By Ownership
16.6.11.7 Argentina Biobanking Market Segmentation, By End-use
16.6.12 Colombia
16.6.12.1 Colombia Biobanking Market Segmentation, By Product
16.6.12.2 Colombia Biobanking Market Segmentation, By Service
16.6.12.3 Colombia Biobanking Market Segmentation, By Biospecimen Type
16.6.12.3 Colombia Biobanking Market Segmentation, By Biobank Type
16.6.12.4 Colombia Biobanking Market Segmentation, By Application
16.6.12.6 Colombia Biobanking Market Segmentation, By Ownership
16.6.12.7 Colombia Biobanking Market Segmentation, By End-use
16.6.13 Rest of Latin America
16.6.13.1 Rest of Latin America Biobanking Market Segmentation, By Product
16.6.13.2 Rest of Latin America Biobanking Market Segmentation, By Service
16.6.13.3 Rest of Latin America Biobanking Market Segmentation, By Biospecimen Type
16.6.13.3 Rest of Latin America Biobanking Market Segmentation, By Biobank Type
16.6.13.4 Rest of Latin America Biobanking Market Segmentation, By Application
16.6.13.6 Rest of Latin America Biobanking Market Segmentation, By Ownership
16.6.13.7 Rest of Latin America Biobanking Market Segmentation, By End-use
17. Company Profiles
17.1 Avantor
17.1.1 Company Overview
17.1.2 Financial
17.1.3 Products/ Services Offered
17.1.4 SWOT Analysis
17.1.5 The SNS View
17.2 BioCision
17.2.1 Company Overview
17.2.2 Financial
17.2.3 Products/ Services Offered
17.2.4 SWOT Analysis
17.2.5 The SNS View
17.3 Becton
17.3.1 Company Overview
17.3.2 Financial
17.3.3 Products/ Services Offered
17.3.4 SWOT Analysis
17.3.5 The SNS View
17.4 Dickinson and Company (BD)
17.4.1 Company Overview
17.4.2 Financial
17.4.3 Products/ Services Offered
17.4.4 SWOT Analysis
17.4.5 The SNS View
17.5 Danaher Corporation
17.5.1 Company Overview
17.5.2 Financial
17.5.3 Products/ Services Offered
17.5.4 SWOT Analysis
17.5.5 The SNS View
17.6 Hamilton Company
17.6.1 Company Overview
17.6.2 Financial
17.6.3 Products/ Services Offered
17.6.4 SWOT Analysis
17.6.5 The SNS View
17.7 Merck KGaA
17.7.1 Company Overview
17.7.2 Financial
17.7.3 Products/ Services Offered
17.7.4 SWOT Analysis
17.7.5 The SNS View
17.8 QIAGEN
17.8.1 Company Overview
17.8.2 Financial
17.8.3 Products/ Services Offered
17.8.4 SWOT Analysis
17.8.5 The SNS View
17.9 Thermo Fisher Scientific, Inc.
17.9.1 Company Overview
17.9.2 Financial
17.9.3 Products/ Services Offered
17.9.4 SWOT Analysis
17.9.5 The SNS View
17.10 Tecan Trading AG.
17.10.1 Company Overview
17.10.2 Financial
17.10.3 Products/ Services Offered
17.10.4 SWOT Analysis
17.10.5 The SNS View
17.11 Taylor-Wharton
17.11.1 Company Overview
17.11.2 Financial
17.11.3 Products/ Services Offered
17.11.4 SWOT Analysis
17.11.5 The SNS View
18. Competitive Landscape
18.1 Competitive Benchmarking
18.2 Market Share Analysis
18.3 Recent Developments
18.3.1 Industry News
18.3.2 Company News
18.3.3 Mergers & Acquisitions
19. Use Case and Best Practices
20. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Neonatal Critical Care Equipment Market size was estimated at USD 3.01 billion in 2023 and is expected to reach USD 5.78 billion by 2032 with a growing CAGR of 7.52% during the forecast period of 2024-2032.
The Healthcare Contract Research Organization Market Size was valued at USD 50.5 billion in 2023 and is expected to reach USD 88.07 billion by 2031, and grow at a CAGR of 7.2% over the forecast period 2024-2031.
The Epilepsy Device Market Size was valued at USD 1.65 billion in 2023 and is expected to reach USD 3.02 billion by 2031 and grow at a CAGR of 8.9% over the forecast period 2024-2031.
The Sanger Sequencing Market Size was valued at USD 2,901.15 Million in 2023, and is expected to reach USD 12,356.57 Million by 2032, and grow at a CAGR of 18.63% Over the Forecast Period of 2024-2032.
The Neurovascular Devices Market Size was valued at USD 3.01 billion in 2023, and is expected to reach USD 4.81 billion by 2030, and grow at a CAGR of 6.05% over the forecast period 2024-2031.
The Dyspnea Treatment Market Size was valued at USD 6.16 Billion in 2023 and is expected to reach USD 11.01 Billion by 2032 and grow at a CAGR of 6.95% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
